Cancer Biologics Market Size, Share & Analysis Report, 2023-2032
The global cancer biologics market size was estimated at USD 95.6 billion in 2022 and is expected to surpass around USD 202.6 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 7.8% during the forecast period 2023 to 2032.
Key Pointers:
Cancer Biologics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 103.06 Billion |
| Market Size by 2032 | USD 202.6 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 7.8% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Drug Class, Application, End-user |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., and Johnson & Johnson Services, Inc. |
Global Cancer Biologics Market Introduction
The cancer biologics market encompasses a range of therapeutic products developed through biotechnology to treat various types of cancer. Biologic drugs are derived from living organisms, such as cells or proteins, and are designed to target specific cancer cells or pathways.
These drugs include monoclonal antibodies, vaccines, and cell-based therapies. These work by enhancing immune response, blocking tumor growth signals, or directly attacking cancer cells.
The market has witnessed significant developments in the past few years, including approval of novel biologic therapies, expansion of targeted therapies, and advancements in immunotherapies.
Targeted therapies, such as HER2-targeted antibodies for breast cancer or EGFR inhibitors for lung cancer, have shown improved treatment outcomes. Immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies have demonstrated remarkable success in certain cancers.
The market continues to evolve with ongoing research and development efforts to discover new therapeutic targets and optimize treatment approaches, aiming to provide more effective and personalized options for cancer patients.
Increase in Incidence of Cancer
Rise in number of cancer cases across the globe has increased the need for effective and targeted therapies to combat this complex disease.
Surge in cancer incidence can be attributed to several factors. Population growth, aging population, and lifestyle changes have contributed to the increasing burden of cancer. Additionally, improved diagnostic techniques and increased awareness have led to better detection and reporting of cancer cases.
Rise in cancer cases has spurred significant advancements in the field of cancer treatment, with a particular focus on biologic drugs. Biologics, derived from living organisms or produced using biotechnology, offer unique advantages over traditional chemotherapy drugs.
Biologics can target specific molecules or pathways involved in cancer growth and progression, leading to more precise and personalized treatment approaches. Increase in cancer incidence has prompted greater research and development efforts in the field of oncology biologics.
Pharmaceutical companies, academic institutions, and research organizations are investing significantly in developing novel biologic drugs and conducting clinical trials to evaluate their safety and efficacy. The focus is not only on improving existing treatments, but also on discovering innovative approaches to combatting cancer.
Advancements in Biotechnology
Advancements in biotechnology are playing a crucial role in driving the global cancer biologics market demand. Biotechnology has revolutionized the field of cancer research and treatment by enabling the development of innovative biologic drugs with enhanced specificity, efficacy, and safety profiles.
One of the key advancements in biotechnology is the ability to produce monoclonal antibodies (mAbs). These biologic drugs are engineered to target specific molecules or proteins expressed on the surface of cancer cells.
By binding to these targets, mAbs can block signaling pathways, inhibit tumor growth, and stimulate immune responses against cancer cells. Development of techniques such as hybridoma technology and recombinant DNA technology has facilitated large-scale production of mAbs with high precision and consistency.
Advent of recombinant DNA technology and genetic engineering has enabled the creation of novel biologic drugs for cancer treatment. This technology enables the manipulation and modification of genes to produce therapeutic proteins with desired characteristics. For instance, the production of erythropoietin (EPO) using recombinant DNA technology has revolutionized the treatment of anemia associated with cancer and chemotherapy.
Development of targeted therapies is another breakthrough in biotechnology that is driving global cancer biologics market value. These therapies focus on specific molecular targets that play a critical role in cancer growth and progression. These are designed to inhibit the activity of these targets and disrupt the signaling pathways involved in tumor development.
Targeted therapies can be small molecules or biologic drugs, such as tyrosine kinase inhibitors or proteasome inhibitors, which selectively target cancer cells while sparing healthy cells.
Biotechnology has facilitated significant advancements in cancer immunotherapies. Immune checkpoint inhibitors, a form of immunotherapy, block inhibitory signals that cancer cells use to evade the immune system's attack.
This approach has shown remarkable success in treating various types of cancer, including melanoma, lung cancer, and bladder cancer. Biotechnology has enabled the production of these biologic drugs that can restore and enhance the body's immune response against cancer cells.
Ability to Specifically Target Cancer Cells Bolstering Monoclonal Antibodies Segment
In terms of drug class, the monoclonal antibodies (mAbs) segment accounted for the largest global cancer biologics market share in 2022. This is ascribed to their unique properties and therapeutic potential.
One of the key reasons for their prominence is the ability to specifically target cancer cells or tumor-associated antigens, while sparing healthy cells. This targeted approach minimizes off-target effects and reduces the risk of systemic toxicity, making mAbs an attractive treatment option.
Monoclonal antibodies continue to be actively researched and developed for novel targets and therapeutic approaches. Emergence of bispecific antibodies, capable of simultaneously binding to two different targets, has gained attention in the past few years. These antibodies can be engineered to engage both cancer cells and immune cells, facilitating the destruction of cancer cells through immune-mediated mechanisms. Bispecific antibodies, such as blinatumomab (Blincyto) for acute lymphoblastic leukemia, represent a promising advancement in cancer treatment.
Advancements in antibody engineering and optimization techniques have enabled the development of next-generation monoclonal antibodies with improved efficacy and reduced immunogenicity. Antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) properties have shown increased tumor-killing capabilities.
Biologic Drugs Specifically Target Underlying Mechanisms of Blood Cancer
Based on application, the blood cancer segment dominated the global cancer biologics industry in 2022. The segment includes leukemia, lymphoma, and multiple myeloma. Blood cancers are a diverse group of malignancies with distinct molecular and genetic characteristics, making them amenable to targeted therapies.
This has led to the development of numerous biologic drugs that specifically target the underlying mechanisms driving blood cancer growth and proliferation. Prevalence of blood cancer is high globally, and a wide range of biologics are available for treatment.
Ongoing research & development efforts in the field of blood cancer biologics continue to expand treatment options. Clinical trials are exploring novel monoclonal antibodies, antibody-drug conjugates, CAR-T cell therapies, and other biologic approaches to further enhance the effectiveness of treatment.
Ability to Provide Comprehensive Care Fueling Hospitals Segment
In terms of end-user, the hospitals segment accounted for the largest market share in 2022. Hospitals have a multidisciplinary approach to cancer care. These settings have a team of healthcare professionals, including medical oncologists, hematologists, radiation oncologists, and specialized nurses, who collaborate to develop comprehensive treatment plans for cancer patients.
This multidisciplinary approach facilitates the integration of cancer biologics into the overall treatment strategy, ensuring proper patient selection, monitoring, and management.
Hospitals often have established partnerships and collaborations with pharmaceutical companies and research institutions. These collaborations enable hospitals to participate in clinical trials and access the latest advancements in cancer biologics. Therefore, they have the advantage of early adoption and integration of new biologic therapies into their treatment protocols.
The ability to provide comprehensive care is another factor driving the hospitals segment. Cancer treatment often involves a combination of therapies, including surgery, radiation therapy, chemotherapy, and biologic therapies. Hospitals can offer all these treatment modalities under one roof, ensuring seamless coordination and continuity of care for patients.
Regional Outlook
As per cancer biologics market trends, North America emerged as a major market for cancer biologics in 2022. This is ascribed to advanced healthcare infrastructure, strong research & development capabilities, favorable regulatory environment, and high healthcare expenditure in the region.
North America is also home to prominent pharmaceutical companies and biotechnology firms that are at the forefront of cancer research and innovation. These companies have the expertise and resources to invest in the development of biologic drugs and conduct clinical trials to evaluate their safety and efficacy.
The region's strong research & development capabilities contribute to the continuous pipeline of new and improved cancer biologics.
Asia Pacific has witnessed steady rise in cancer cases, attributed to factors such as population growth, aging population, and lifestyle changes. This surge in cancer incidence has increased demand for effective cancer treatments, including biologic drugs.
Improving healthcare infrastructure is another crucial factor driving the cancer biologics market size in Asia Pacific. Countries in the region have been investing significantly in healthcare infrastructure, including the establishment of advanced hospitals, cancer centers, and research institutes. This improved infrastructure enables the development, production, and distribution of biologic drugs for cancer treatment, enhancing patient access to these therapies.
Key Developments in Global Cancer Biologics Market
In March 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the Biologics License Application (BLA) for sintilimab injection, an investigational medicine. Sintilimab is a PD-1 inhibitor intended for use in combination with pemetrexed and platinum chemotherapy as a first-line treatment for individuals diagnosed with nonsquamous non-small cell lung cancer (NSCLC).
On May 19, 2023, AbbVie announced the approval of EPKINLYTM (epcoritamab-bysp) by the U.S. Food and Drug Administration (FDA). This marks a significant milestone as EPKINLYTM becomes the first and only T-cell engaging bispecific antibody approved for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), who have undergone two or more lines of systemic therapies.
Some of the prominent players in the Cancer Biologics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Cancer Biologics market.
By Drug Class
By Application
By End-user
By Region
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers